Is the iron donor lipocalin 2 implicated in the pathophysiology of hereditary hemochromatosis?

Hepatology

Volumn 49, Issue 3, 2009, Pages 1012-1016

  Huang, Hua ^a   Akira, Shizuo ^b   Santos, Manuela M ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HFE PROTEIN; IRON; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSFERRIN; ACUTE PHASE PROTEIN; HFE PROTEIN, MOUSE; HLA ANTIGEN CLASS 1; LCN2 PROTEIN, MOUSE; LIPOCALIN; MEMBRANE PROTEIN; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; FEMALE; HEMOCHROMATOSIS; IRON BLOOD LEVEL; IRON INTAKE; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; LIVER METABOLISM; MOUSE; MOUSE MUTANT; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; TISSUE LEVEL; TRANSFERRIN BLOOD LEVEL; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; LIVER CELL; METABOLISM; MUTATION; PATHOLOGY;

ACUTE-PHASE PROTEINS; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HEMOCHROMATOSIS; HEPATOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; IRON; LIPOCALINS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; ONCOGENE PROTEINS;

EID: 63349099823     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22699     Document Type: Article

References (43)

1. Ponka P, Lok CN. The transferrin receptor: Role in health and disease. Int J Biochem Cell Biol 1999;31:1111-1137.
2. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, Andrews NC. Nramp2 is mutated in the anemic Belgrade (b) rat: Evidence of a role for Nramp2 in endosomal iron transport. Proc Natl Acad Sci U S A 1998;95:1148-1153.
3. Craven CM, Alexander J, Eldridge M, Kushner JP, Bernstein S, Kaplan J. Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: A rodent model for hemochromatosis. Proc Natl Acad Sci U S A 1987;84:3457-3461.
4. Sheth S, Brittenham GM. Genetic disorders affecting proteins of iron metabolism: Clinical implications. Ann Rev Med 2000;51:443-464.
5. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
6. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004;350:2383-2397.
7. Loreal O, Gosriwatana I, Guyader D, Porter J, Brissot P, Hider RC. Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. J Hepatol 2000;32:727-733.
8. Chua AC, Olynyk JK, Leedman PJ, Trinder D. Nontransferrin-bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis. Blood 2004;104:1519-1525.
9. Brissot P, Wright TL, Ma WL, Weisiger RA. Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 1985;76:1463-1470.
10. Gunshin H, Fujiwara Y, Custodio AO, DiRenzo C, Robine S, Andrews NC. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 2005;115:1258-1266.
11. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-10432.
12. Kaplan J. Mechanisms of cellular iron acquisition: Another iron in the fire. Cell 2002;111:603-606.
13. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002;10: 1033-1043.
14. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, Du T, et al. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002;10:1045-1056.
15. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the realtime indicator of active kidney damage. Kidney Int 2007;71:967-970.
16. Devarajan P. Neutrophil gelatinase-associated lipocalin: New paths for an old shuttle. Cancer Ther 2007;5:463-470.
17. Hanai J, Mammoto T, Seth P, Mori K, Karumanchi SA, Barasch J, et al. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem 2005;280:13641-13647.
18. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004;15:3073-3082.
19. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005;115:610-621.
20. Elangovan N, Lee Y-C, Tzeng W-F, Chu S-T. Delivery of ferric ion to mouse spermatozoa is mediated by lipocalin internalization. Biochem Biophys Res Commun 2004;319:1096-1104.
21. Li J-Y, Ram G, Gast K, Chen X, Barasch K, Mori K, et al. Detection of intracellular iron by its regulatory effect. Am J Physiol Cell Physiol 2004; 287:C1547-C1559.
22. Devireddy LR, Teodoro JG, Richard FA, Green MR. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 2001;293:829-834.
23. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432:917-921.
24. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2006;103:1834-1839.
25. Miharada K, Hiroyama T, Sudo K, Danjo I, Nagasawa T, Nakamura Y. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells. J Cell Physiol 2008;215:526-537.
26. Miharada K, Hiroyama T, Sudo K, Nagasawa T, Nakamura Y. Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion. FASEB J. 2005;19:1881-1883.
27. Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett 2005;579:773-777.
28. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem 1992;267:26172-26180.
29. Meilinger M, Haumer M, Szakmary KA, Steinbock F, Scheiber B, Goldenberg H, et al. Removal of lactoferrin from plasma is mediated by binding to low density lipoprotein receptor-related protein/α2-macroglobulin receptor and transport to endosomes. FEBS Lett 1995;360:70-74.
30. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007;18:407-413.
31. Levy JE, Montross LK, Cohen DE, Fleming MD, Andrews NC. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood 1999;94:9-11.
32. Constante M, Jiang W, Wang D, Raymond V-A, Bilodeau M, Santos MM. Distinct requirements for Hfe in basal and induced hepcidin levels in iron overload and inflammation. Am J Physiol Gastrointest Liver Physiol 2006;291:G229-G237.
33. Makui H, Soares RJ, Jiang W, Constante M, Santos MM. Contribution of Hfe expression in macrophages to the regulation of hepatic hepcidin levels and iron loading. Blood 2005;106:2189-2195.
34. Ahmad KA, Ahmann JR, Migas MC, Waheed A, Britton RS, Bacon BR, et al. Decreased liver hepcidin expression in the hfe knockout mouse. Blood Cells Mol Dis 2002;29:361-366.
35. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000;23:185-192.
36. Kaplan J, Jordan I, Sturrock A. Regulation of the transferrin-independent iron transport system in cultured cells. J Biol Chem 1991;266:2997-3004.
37. Inman RS, Wessling-Resnick M. Characterization of transferrin-independent iron transport in K562 cells. Unique properties provide evidence for multiple pathways of iron uptake. J Biol Chem 1993;268:8521-8528.
38. Randell EW, Parkes JG, Olivieri NF, Templeton DM. Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J Biol Chem 1994;269:16046-16053.
39. Tsushima RG, Wickenden AD, Bouchard RA, Oudit GY, Liu PP, Backx PH. Modulation of iron uptake in heart by L-Type Ca2+ channel modifiers: possible implications in iron overload. Circ Res 1999;84:1302-1309.
40. Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc Natl Acad Sci U S A 2006;103:13612-13617.
41. Gaasch J, Geldenhuys W, Lockman P, Allen D, Van der Schyf C. Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures. Neurochem Res 2007;32:1686-1693.
42. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003;9:1187-1194.
43. Taylor KM, Morgan HE, Johnson A, Nicholson RI. Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Letters 2005;579:427-432.